Inhibition of NF-κB with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro

Anticancer Research

Volumn 21, Issue 1 A, 2001, Pages 39-44

  Milligan, S A ^a   Nopajaroonsri, C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Lung cancer; NF B; Proteasome

Indexed keywords

DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ACETYLCYSTEINE; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA FRAGMENTATION; DNA-BINDING PROTEINS; HUMANS; I-KAPPA B PROTEINS; LEUPEPTINS; LUNG NEOPLASMS; MULTIENZYME COMPLEXES; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035064358     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Progress in understanding the molecular pathogenesis of human lung cancer
2. Aberrant rel/nfkb genes and activity in human cancer
3. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
4. Suppression of TNF-α-induced apoptosis by NF-κB
5. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
6. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
7. Enhanced degradation of IkB-a contributes to endogenous activation of NF-κB in Hs294t melanoma cells
8. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
9. IκB-α gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-a-mediated cell death
10. Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs
11. Control of apoptosis by Rel/NF-κB transcription factors
12. NF-κB and Rel proteins: Evolutionary conserved mediators of immune responses
13. Diverse agents act at multiple levels to inhibit the Rel/NFκB signal transduction pathway
14. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
15. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells
16. p53 mutations, and p53-heat shock 70 complexes in human lung carcinoma cell lines
17. Differential regulation of extracellular signal-regulated kinase and nuclear factor-κB signal transduction pathways by hydrogen peroxide and tumor necrosis factor
18. Inhibition of IκB-α and IκB-β proteolysis by calpain inhibitor I blocks nitric oxide synthesis
19. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases
20. IkB-α overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor-α-induced apoptosis
21. Proteasome inhibition: A new strategy in cancer treatment
22. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
23. Squamous cell carcinomas and increased apoptosis in skin with inhibited rel/nuclear factor-κB signaling
24. The role of the ubiquitin-proteasome pathway in apoptosis. Review
25. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
26. Proteasome inhibitors: A novel class of potent and effective antitumor agents